By Josh White
Date: Thursday 07 Dec 2023
(Sharecast News) - Iron deficiency-focussed pharmaceuticals company Shield Therapeutics announced significant achievements in the US commercialisation of Accrufer on Thursday.
By Josh White
Date: Monday 21 Mar 2022
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics announced on Monday that KYE Pharmaceuticals has submitted a new drug submission to Health Canada, for the regulatory review and approval of the iron therapy 'Accrufer'.
By Josh White
Date: Thursday 17 Feb 2022
(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics reported total 2021 revenue of £1.5m in a trading update on Thursday, in line with market expectations.
Currency | UK Pounds |
Share Price | 2.05p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 12.50 |
52 Week Low | 1.23 |
Volume | 690,953 |
Shares Issued | 782.06m |
Market Cap | £16.03m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 0 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 1 |
No dividends found |
Time | Volume / Share Price |
16:18 | 50,000 @ 2.01p |
15:31 | 18,000 @ 2.10p |
14:55 | 1,000 @ 2.00p |
14:55 | 8,000 @ 2.01p |
12:16 | 32,000 @ 2.10p |
You are here: research